These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Rapid improvement of uremic neuropathy on short high-efficiency hemodialysis with special reference to middle molecules. Manohar NL; Gorfien PC; Namba T; Louis BM; Lipner HI ASAIO Trans; 1987; 33(3):274-9. PubMed ID: 3675953 [No Abstract] [Full Text] [Related]
24. Renal handling of uremic middle molecules. a study with the isolated perfused rat kidney. Schindhelm K; Schlatter E; Schurek HJ; Stolte H Nephron; 1982; 30(2):166-72. PubMed ID: 7099324 [TBL] [Abstract][Full Text] [Related]
25. A bench to bedside view of uremic toxins. Vanholder R; Baurmeister U; Brunet P; Cohen G; Glorieux G; Jankowski J; J Am Soc Nephrol; 2008 May; 19(5):863-70. PubMed ID: 18287557 [TBL] [Abstract][Full Text] [Related]
38. Extracorporeal removal of uremic toxins: can we still do better? Eloot S; Ledebo I; Ward RA Semin Nephrol; 2014 Mar; 34(2):209-27. PubMed ID: 24780474 [TBL] [Abstract][Full Text] [Related]
39. What remains of the "middle molecule" hypothesis today? Brunner H; Mann H Contrib Nephrol; 1985; 44():14-39. PubMed ID: 3886282 [No Abstract] [Full Text] [Related]
40. Middle molecules as a marker of uremic toxins. Wu ZG; Liao LT; Cai ZH; Lu ZN; Cai YD; Sheng PF Adv Exp Med Biol; 1987; 223():33-7. PubMed ID: 3447449 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]